Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 22, 2009

Biovitrum to Divest R&D Segment Cambridge Biotechnology

  • Biovitrum decided to spin out its small molecule R&D subsidiary, Cambridge Biotechnology (CBT), and a range of primary care projects. Biovitrum will focus on specialist pharmaceuticals and protein therapeutics.

    CBT’s pipeline includes a Phase II neuropathic pain project and obesity candidates in Phase II and Phase I trials. The company also has a leptin mimetic preclinical drug in obesity as well as a pain and inflammation preclinical program and four discovery programs in pain and inflammation.

    Biovitrum, on the other hand, retains hemophilia and fat malabsorption clinical programs. Both are in mid-stage development. The firm reported net revenues from January to September 2008 of SEK 826.3 million, or $99.78 million. Its portfolio has therapies for oncology, rheumatoid arthritis, hemophilia, anticoagulation, and calcium hemostasis, including three biologics that it recently bought from Amgen for $150 million.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »